A Purposeful, Precise and Powerful Approach to Address the Global Antibiotic Resistance Crisis
Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections.
Antibiotic overuse has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which common infections can be serious or life-threatening. Additionally, the use of broad-spectrum antibiotics is known for disrupting the ecology of the human microbiome, leading to disease.
To combat the rapidly growing global problem of drug-resistant bacterial infections, Armata is using its proprietary bacteriophage-based technology.
Armata is headquartered in Marina del Rey, California, in a 35,000 square foot facility built for phage product development with capabilities spanning bench to clinic. Microbiologists, dedicated to the discovery of natural phages, are complemented by a team of scientists that harness the natural power and diversity of these phages through synthetic biology and engineering. In-house formulation development allows tailoring of the drug product to an indication, and Armata’s cGMP drug manufacturing suites and Quality Unit enable the production, purification, testing and release of clinical trial material. All of this is embedded in a seasoned team of professionals with extensive clinical development experience.